Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma genitalium Infections in a High-Risk Population
Abstract
:1. Introduction
2. Patients and Methods
2.1. Sample Population
2.2. STI Testing
2.3. Antibiotic Resistance Screening
2.4. Statistical Analysis
3. Results
Resistance
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lis, R.; Rowhani-Rahbar, A.; Manhart, L.E. Mycoplasma genitalium Infection and Female Reproductive Tract Disease: A Meta-analysis. Clin. Infect. Dis. 2015, 61, 418–426. [Google Scholar]
- Frenzer, C.; Egli-Gany, D.; Vallely, L.M.; Vallely, A.J.; Low, N. Adverse pregnancy and perinatal outcomes associated with Mycoplasma genitalium: Systematic review and meta-analysis. Sex. Transm. Infect. 2022, 98, 222–227. [Google Scholar]
- Torrone, E.A.; Kruszon-Moran, D.; Philips, C.; Morris, M.R.; Bowden, K.E.; Papp, J.; Bachmann, L.H.; Weinstock, H.; Kersh, E.N. Prevalence of Urogenital Mycoplasma genitalium Infection, United States, 2017 to 2018. Sex. Transm. Dis. 2021, 48, e160–e162. [Google Scholar]
- Gottesman, T.; Yossepowitch, O.; Samra, Z.; Rosenberg, S.; Dan, M. Prevalence of Mycoplasma genitalium in men with urethritis and in high risk asymptomatic males in Tel Aviv: A prospective study. Int. J. STD AIDS 2017, 28, 127–132. [Google Scholar]
- Salado-Rasmussen, K.; Jensen, J.S. Mycoplasma genitalium Testing Pattern and Macrolide Resistance: A Danish Nationwide Retrospective Survey. Clin. Infect. Dis. 2014, 59, 24–30. [Google Scholar]
- Tully, J.G.; Taylor-Robinson, D.; Cole, R.M.; Rose, D.L. A newly discovered mycoplasma in the human urogenital tract. Lancet 1981, 1, 1288–1291. [Google Scholar]
- Tagg, K.A.; Jeoffreys, N.J.; Couldwell, D.L.; Donald, J.A.; Gilbert, G.L. Fluoroquinolone and Macrolide Resistance-Associated Mutations in Mycoplasma genitalium. J. Clin. Microbiol. 2013, 51, 2245–2249. [Google Scholar] [PubMed]
- Couldwell, D.L.; Tagg, K.A.; Jeoffreys, N.J.; Gilbert, G.L. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int. J. STD AIDS 2013, 24, 822–828. [Google Scholar] [PubMed]
- Bradshaw, C.S.; Chen, M.Y.; Fairley, C.K. Persistence of Mycoplasma genitalium Following Azithromycin Therapy. PLoS ONE 2008, 3, e3618. [Google Scholar]
- Getman, D.; Jiang, A.; O’Donnell, M.; Cohen, S. Mycoplasma genitalium Prevalence, Coinfection, and Macrolide Antibiotic Resistance Frequency in a Multicenter Clinical Study Cohort in the United States. J. Clin. Microbiol. 2016, 54, 2278–2283. [Google Scholar]
- Murray, G.L.; Bodiyabadu, K.; Danielewski, J.; Garland, S.M.; Machalek, D.A.; Fairley, C.K.; Jensen, J.S.; Williamson, D.A.; Tan, L.Y.; Mokany, E.; et al. Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations. J. Infect. Dis. 2020, 221, 1017–1024. [Google Scholar]
- Jensen, J.S.; Cusini, M.; Gomberg, M.; Moi, H.; Wilson, J.; Unemo, M. 2021 European guideline on the management of Mycoplasma genitalium infections. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 641–650. [Google Scholar]
- Lau, A.; Bradshaw, C.S.; Lewis, D.; Fairley, C.K.; Chen, M.Y.; Kong, F.Y.S.; Hocking, J.S. The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium: A Systematic Review and Meta-analysis. Clin. Infect. Dis. 2015, 61, 1389–1399. Available online: https://pubmed.ncbi.nlm.nih.gov/26240201/ (accessed on 17 August 2024). [PubMed]
- Read, T.R.H.; Fairley, C.K.; Murray, G.L.; Jensen, J.S.; Danielewski, J.; Worthington, K.; Doyle, M.; Mokany, E.; Tan, L.; Chow, E.P.; et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin. Infect. Dis. 2019, 68, 554–560. [Google Scholar]
- Durukan, D.; Read, T.R.H.; Murray, G.; Doyle, M.; Chow, E.P.F.; Vodstrcil, L.A.; Fairley, C.K.; Aguirre, I.; Mokany, E.; Tan, L.Y.; et al. Resistance-Guided Antimicrobial Therapy Using Doxycycline–Moxifloxacin and Doxycycline–2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability. Clin. Infect. Dis. 2020, 71, 1461–1468. [Google Scholar]
- Workowski, K.A.; Bachmann, L.H.; Chan, P.A.; Johnston, C.M.; Muzny, C.A.; Park, I.; Reno, H.; Zenilman, J.M.; Bolan, G.A. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm. Rep. 2021, 70, 1–187. [Google Scholar]
- Kridin, K.; Ingram, B.; Becker, D.; Shiloah, N.; Azrad, M.; Habib, S.; Peretz, A. Sexually Transmitted Diseases in Northern Israel: Insights From a Large Referral Laboratory. J. Low. Genit. Tract. Dis. 2023, 27, 51–55. [Google Scholar]
- Machalek, D.A.; Tao, Y.; Shilling, H.; Jensen, J.S.; Unemo, M.; Murray, G.; Chow, E.P.; Low, N.; Garland, S.M.; Vodstrcil, L.A.; et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: A systematic review and meta-analysis. Lancet Infect. Dis. 2020, 20, 1302–1314. [Google Scholar] [PubMed]
- Murray, G.L.; Bodiyabadu, K.; Vodstrcil, L.A.; Machalek, D.A.; Danielewski, J.; Plummer, E.L.; Garland, S.M.; Whiley, D.M.; Sweeney, E.L.; Bradshaw, C.S. parC Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure. Antimicrob. Agents Chemother. 2022, 66, e00278–22. [Google Scholar]
- Mycoplasma genitalium—STI Treatment Guidelines [Internet]. Available online: https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm (accessed on 17 August 2024).
- Jensen, J.S.; Bradshaw, C.S.; Tabrizi, S.N.; Fairley, C.K.; Hamasuna, R. Azithromycin treatment failure in Mycoplasma genitalium -positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin. Infect. Dis. 2008, 47, 1546–1553. [Google Scholar] [PubMed]
- Parnham, M.J.; Erakovic Haber, V.; Giamarellos-Bourboulis, E.J.; Perletti, G.; Verleden, G.M.; Vos, R. Azithromycin: Mechanisms of action and their relevance for clinical applications. Pharmacol. Ther. 2014, 143, 225–245. [Google Scholar]
- Poehlsgaard, J.; Douthwaite, S. The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 2005, 3, 870–881. [Google Scholar]
- Kanoh, S.; Rubin, B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010, 23, 590–615. [Google Scholar] [PubMed]
- Sandri, A.; Carelli, M.; Visentin, A.; Savoldi, A.; De Grandi, G.; Mirandola, M.; Lleo, M.M.; Signoretto, C.; Cordioli, M. Mycoplasma genitalium antibiotic resistance-associated mutations in genital and extragenital samples from men-who-have-sex-with-men attending a STI clinic in Verona, Italy. Front. Cell. Infect. Microbiol. 2023, 13, 1155451. [Google Scholar]
- Bradley, I.; Varma, R.; Knight, V.; Iliakis, D.; McNally, L.; Jalocon, D.; McNally, L.; Jalocon, D.; Jeoffreys, N.; Chen, S.; et al. Prevalence of rectal Mycoplasma genitalium and macrolide resistance in men who have sex with men attending Sydney Sexual Health Centre. Sex. Health 2020, 17, 114–120. [Google Scholar] [PubMed]
- Berçot, B.; Charreau, I.; Rousseau, C.; Delaugerre, C.; Chidiac, C.; Pialoux, G.; Capitant, C.; Bourgeois-Nicolaos, N.; Raffi, F.; Pereyre, S.; et al. High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial. Clin. Infect. Dis. 2021, 73, e2127–e2133. [Google Scholar]
- Couldwell, D.L.; Lewis, D.A. Mycoplasma genitalium infection: Current treatment options, therapeutic failure, and resistance-associated mutations. Infect. Drug Resist. 2015, 8, 147–161. [Google Scholar] [PubMed]
- Hamasuna, R.; Le, P.T.; Kutsuna, S.; Furubayashi, K.; Matsumoto, M.; Ohmagari, N.; Fujimoto, N.; Matsumoto, T.; Jensen, J.S. Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. PLoS ONE 2018, 13, e0198355. [Google Scholar]
- van der Schalk, T.E.; Braam, J.F.; Kusters, J.G. Molecular basis of antimicrobial resistance in Mycoplasma genitalium. Int. J. Antimicrob. Agents 2020, 55, 105911. [Google Scholar]
- Murray, G.L.; Bradshaw, C.S.; Bissessor, M.; Danielewski, J.; Garland, S.M.; Jensen, J.S.; Fairley, C.K.; Tabrizi, S.N. Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. Emerg. Infect. Dis. 2017, 23, 809–812. [Google Scholar]
- Kenyon, C.; Herrmann, B.; Hughes, G.; de Vries, H.J.C. Management of asymptomatic sexually transmitted infections in Europe: Towards a differentiated, evidence-based approach. Lancet Reg. Health Eur. 2023, 34, 100743. [Google Scholar]
- Wood, G.E.; Bradshaw, C.S.; Manhart, L.E. Update in Epidemiology and Management of Mycoplasma genitalium Infections. Infect. Dis. Clin. N. Am. 2023, 37, 311–333. [Google Scholar]
Characteristic | N (%) |
---|---|
Number of patients | 142 |
Mean age | 31.7 (SD 9.3) |
Gender—female | 50 (35.2%) |
Symptomatic | 38 (26.8%) |
History of STI | 66 (46.5%) |
Previous antibiotic treatment | 13 (9.2%) |
MSM | 64 (45.1%) |
More than 20 lifetime sexual partners | 114 (80.3%) |
More than 20 sexual partners in past three months | 37 (26.1%) |
Reported receiving money for sex | 27 (19%) |
Reported substance use | 58 (40.8%) |
HIV positive | 7 (4.9%) |
Concomitant STI | 41 (28.8%) |
Concomitant Chlamydia trachomatis | 26 (18.2%) |
Concomitant Neisseria gonorrhoeae | 15 (10.5%) |
Bivariate Analysis | Multivariate Analysis | ||
---|---|---|---|
p Value | RR * (95% CI) | p Value | |
More than one site involved | 0.05 | ||
Urinary infection | 0.544 | ||
Rectal infection | 0.038 | ||
Throat infection | 0.534 | ||
Concomitant Chlamydia trachomatis | 0.889 | ||
Concomitant Neisseria gonorrhoeae | 0.945 | ||
Male gender | <0.001 | ||
Symptoms | 0.584 | ||
Past STI * | <0.001 | 2.333 (1.018–5.347) | 0.45 |
Previous antibiotic treatment | 0.386 | ||
MSM * | <0.001 | 7.011 (3.009–16.336) | <0.001 |
20 or more lifetime sexual partners | <0.045 | ||
5 or less sexual partners in the last three months | 0.001 | 0.685 (0.494–0.950) | 0.24 |
Reported receiving money for sex | 0.014 | ||
Substance use | 0.046 | ||
HIV * status | 0.356 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hackett, A.; Yossepowitch, O.; Goor, Y.; Sheffer, R.; Schwartz, O.; Sheftel, Y.; Weiss, Y.; Maor, Y. Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma genitalium Infections in a High-Risk Population. J. Clin. Med. 2024, 13, 4924. https://doi.org/10.3390/jcm13164924
Hackett A, Yossepowitch O, Goor Y, Sheffer R, Schwartz O, Sheftel Y, Weiss Y, Maor Y. Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma genitalium Infections in a High-Risk Population. Journal of Clinical Medicine. 2024; 13(16):4924. https://doi.org/10.3390/jcm13164924
Chicago/Turabian StyleHackett, Asher, Orit Yossepowitch, Yael Goor, Rivka Sheffer, Orna Schwartz, Yonatan Sheftel, Yarden Weiss, and Yasmin Maor. 2024. "Prevalence and Risk Factors for Antimicrobial Resistance of Mycoplasma genitalium Infections in a High-Risk Population" Journal of Clinical Medicine 13, no. 16: 4924. https://doi.org/10.3390/jcm13164924